Andrew Cheng
Fortune : 561 365 $ au 30/06/2026
Fortune : 561 365 $ au 30/06/2026
Andrew Cheng is currently Chairman, President & Chief Executive Officer at Avere Therapeutics, Inc. Dr. Cheng is an Independent Director at Vera Therapeutics, Inc. since 2017.
Dr. Cheng is a Director at Boys & Girls Clubs of Metro Los Angeles.
Dr. Cheng is an Independent Director at TCGX Acquisition Corp.
starting in 2026.
Formerly, Dr. Cheng was President, Chief Executive Officer & Director at Akero Therapeutics, Inc. from 2018 to 2025.
Dr. Cheng was an Independent Director at Arbutus Biopharma Corp.
from 2019 to 2022.
Dr. Cheng was a Director at Syntimmune, Inc. Dr. Cheng was a Director at Global Virus Network.
Dr. Cheng was a Non-Executive Director at MorphoSys AG from 2022 to 2024.
Dr. Cheng was Chief Medical Officer & Executive Vice President at Gilead Sciences, Inc. in 2018.
Dr. Cheng completed undergraduate studies at The Johns Hopkins University in 1988.
Dr. Cheng earned a doctorate from Columbia University College of Physicians & Surgeons in 1996.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2026 | 17 488 ( 0,02 % ) | 561 365 $ | 31/07/2026 | |
1,39 % | 05/08/2026 | 30 000 ( 1,39 % ) | 0 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| VERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/05/2017 |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Operates as a Non-profit organization that provides proven programming services | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Directeur Général | 09/12/2025 |
| MORPHOSYS AG | Directeur/Membre du Conseil | 06/06/2024 |
| ARBUTUS BIOPHARMA CORPORATION | Directeur/Membre du Conseil | 25/05/2022 |
| GILEAD SCIENCES, INC. | Directeur Technique/Scientifique/R&D | 07/09/2018 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Arbutus Biopharma Corp.
Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Engages in developing novel antibody therapies and severe toxicities in bio pharma industry | Health Technology |
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Researches on essential and critical defense against viral disease | Commercial Services |
Columbia University College of Physicians & Surgeons
Columbia University College of Physicians & Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akero Therapeutics, Inc.
Akero Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for patients with metabolic diseases | Health Technology |
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Operates as a Non-profit organization that provides proven programming services | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national